Subscribe to Here’s the Deal, our politics
newsletter for analysis you won’t find anywhere else.
Thank you. Please check your inbox to confirm.
By John Yang, Harry Zahn
In our news wrap Wednesday, the European Union says it will retaliate against attacks on its energy networks after explosions damaged two pipelines in the Baltic Sea, Palestinian authorities say Israeli forces killed four Palestinians and wounded more than 40…
Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer's drug Aduhelm less than a year after the medication's launch triggered a backlash from experts, doctors and insurers.
By Matthew Perrone, Tom Murphy, Associated Press
Biogen is slashing the price of its Alzheimer's treatment months after the drug debuted to widespread criticism for an initial cost that can reach $56,000 annually.
By Tom Murphy, Associated Press
The Food and Drug Administration has approved new prescribing instructions that are likely to limit use of a controversial new Alzheimer's drug.
By Matthew Perrone, Associated Press
By Amna Nawaz, Claire Mufson
The FDA on Monday approved the first new drug to treat Alzheimer's disease in nearly two decades. Federal health officials said it may help slow the brain-destroying disease's progression, but the approval goes against the agency's independent advisers who said…
By Marilynn Marchione, AP Chief Medical Writer, Matthew Perrone, Associated Press
The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked.
By Kate McDonald
Nearly 6 million Americans currently live with Alzheimer’s disease, and the number continues to rise. For many, this terminal diagnosis represents the start of a life with limitations. But as a program called Contemporary Journeys shows, it's a life that…
By John Yang, Leah Nagy
In Nashville, the nonprofit Music for Seniors connects the city’s musicians with its older residents in an effort to build community and improve seniors’ quality of life. Now, the organization is teaming up with researchers at Vanderbilt University to see…
By Miles O'Brien
At age 61, Judi Polak is five years into a bleak diagnosis: Alzheimer’s disease. But last year she made medical history in a clinical trial, when a team of scientists, engineers and practitioners deployed a novel device to take aim…
Support Provided By: